News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TRANSGENE (ENX:TNG) Announces Promising Results In An Update From The Phase 2b Part Of TIME Trial With TG4010 In Advanced Non-Small Cell Lung Cancer


5/27/2014 10:40:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:

Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) today announced promising results in an update incorporating more mature data from the Phase 2b part of the Phase 2b/3 TIME trial1 with TG4010 MUC-1 targeted immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES